REGENXBIO Inc. (RGNX)
| Market Cap | 1.20B |
| Revenue (ttm) | 93.14M |
| Net Income (ttm) | -212.42M |
| Shares Out | 42.77M |
| EPS (ttm) | -5.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 442,944 |
| Open | 26.53 |
| Previous Close | 26.58 |
| Day's Range | 26.10 - 28.05 |
| 52-Week Range | 25.80 - 49.63 |
| Beta | 0.92 |
| Analysts | Buy |
| Price Target | 58.33 (+108.6%) |
| Earnings Date | Nov 2, 2021 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It i...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for REGENXBIO stock is "Buy." The 12-month stock price forecast is 58.33, which is an increase of 108.62% from the latest price.
News
REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using...
ROCKVILLE, Md., Jan. 10, 2022 /PRNewswire/ -- ASCENTTM, a Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada Pivotal trials exp...
REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne M...
ROCKVILLE, Md., Jan. 6, 2022 /PRNewswire/ -- Potential one-time gene therapy for the treatment of Duchenne includes a novel, optimized microdystrophin transgene and REGENXBIO's proprietary NAV® AAV8 vec...
REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status
REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.
RegenXbio's Duchenne Gene Therapy Secures FDA Orphan Drug Tag
The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (Duchenne). Duchenne is a genetic disorder charact...
REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of D...
ROCKVILLE, Md., Nov. 22, 2021 /PRNewswire/ -- Potential one-time gene therapy for the treatment of Duchenne, includes a novel, optimized microdystrophin transgene and REGENXBIO's proprietary NAV® AAV8 v...
REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using ...
ROCKVILLE, Md., Nov. 12, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 in Phase II AAVIATE® trial for the treatment of wet AMD continues to be well tolerated in 50 patients from Cohorts 1-3 wi...
REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie
ROCKVILLE, Md., Nov. 9, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its Collaboration and License Agreement with AbbVie to develop and commercialize RGX-314, a pote...
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences, which will each be held in a virtual meeting format:...
REGENXBIO Announces RGX-314 Data Presentation at the American Academy of Ophthalmology 2021 Annual Meeting
ROCKVILLE, Md., Nov. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that data from the RGX-314 clinical trials will be presented in an oral presentation at the American Academy of...
Regenxbio (RGNX)'s Technical Outlook is Bright After Key Golden Cross
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -57.47% and -37.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights
ROCKVILLE, Md., Nov. 2, 2021 /PRNewswire/ -- Announced eye care collaboration with AbbVie to develop and commercialize RGX-314 AbbVie and REGENXBIO form a strategic partnership combining eye care and ge...
Can Regenxbio (RGNX) Climb 77% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positi...
REGENXBIO to Host Conference Call on November 2 to Discuss Third Quarter 2021 Financial Results and Recent Operationa...
ROCKVILLE, Md., Oct. 26, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, November 2, 2021, at 4:30 p.m.
Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME). The data were prese...
REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retin...
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious adverse events No intraocular inflammation observed...
What's Next For REGENXBIO Stock After A 20% Fall Yesterday?
REGENXBIO stock declined by 20% yesterday, while it is down 26% in the last ten trading days. In comparison, the broader S&P500 index declined by 1.4% over the same period.
REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using S...
ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 50 patients in Cohorts 1-3 with no drug-related serious adverse events Positive initial data from Cohort...
REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina Specialists Annual Meeting
ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ -- Data for Cohort 1 with three months of follow-up from the RGX-314 Phase II trial for the treatment of diabetic retinopathy (ALTITUDE®) to be presented REGENX...
REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call
ROCKVILLE, Md., Sept. 27, 2021 /PRNewswire/ -- Interim data for Cohort 1 with six months of follow-up from the RGX-314 Phase II trial for the treatment of wet AMD (AAVIATE®) to be presented REGENXBIO to...
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy
AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.
REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie
REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.
REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last?
REGENXBIO (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th...
Eyes Have It in AbbVie Deal With Regenxbio
To expand its footprint in eye care, AbbVie Inc.( ABBV , Financial) has struck a billion-dollar deal to gain access to a gene therapy used to treat several common kinds of eye disease. The Chicago-area ...
Why Regenxbio Stock Is Way Up Today
American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration.